• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项针对日本65岁及以上老年人的23价肺炎球菌多糖疫苗(PPSV23)再接种覆盖率及医生态度的全国性调查。

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude.

作者信息

Nakamura Atsushi, Kawakami Kenji, Wakana Akira, Folaranmi Temitope A, Iino Tomoharu

机构信息

Medical Affairs Vaccine, MSD K.K , Tokyo, Japan.

Medical Division, NTT East Izu Hospital , Shizuoka, Japan.

出版信息

Hum Vaccin Immunother. 2020 Sep 1;16(9):2292-2299. doi: 10.1080/21645515.2020.1717184. Epub 2020 Feb 11.

DOI:10.1080/21645515.2020.1717184
PMID:32045317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7553671/
Abstract

In July 2017, the Japanese Association for Infectious Diseases issued guidance for the administration of the PPSV23 revaccination. Despite increasing recognition of its protective benefits, levels of PPSV23 revaccination coverage rate in Japanese elderly population are unclear at present. Here, we report the results of a survey to know PPSV23 revaccination rates among elderly patients aged 65 and older. We asked an array of questions related to PPSV23 revaccination to Elderly adults and doctors across Japan via Web-based surveys in June 2018. The sampled population consisted of 5,085 men and women aged 65 and older. The PPSV23 revaccination coverage rate was estimated by survey questions regarded vaccination counts, intervals, and vaccine type. In addition, 400 internal medicine physicians were surveyed and asked about their reasons for recommending PPSV23 revaccination to elderly patients. In total, 1,648 elderly adults had received at least one PPSV23 dose; of these, 58 had received it at least twice (revaccination coverage rate: 3.5%). The most commonly cited justification for revaccination with PPSV23 among the surveyed physicians was that the benefits of revaccination exceed the risks of revaccination. In addition, multivariate analysis showed revaccinated status was most strongly associated with recommendations from peers (e.g. spouse, family, friends) among elderly subjects. This study reports PPSV23 revaccination coverage rate among Japanese adults aged 65 and older for the first time and concludes that the coverage rate is very low.

摘要

2017年7月,日本传染病协会发布了23价肺炎球菌多糖疫苗(PPSV23)再接种的管理指南。尽管人们越来越认识到其保护作用,但目前日本老年人群中PPSV23再接种的覆盖率尚不清楚。在此,我们报告一项调查结果,以了解65岁及以上老年患者中PPSV23的再接种率。2018年6月,我们通过网络调查向日本各地的老年人和医生询问了一系列与PPSV23再接种相关的问题。抽样人群包括5085名65岁及以上的男性和女性。PPSV23再接种覆盖率是通过关于接种次数、间隔时间和疫苗类型的调查问题来估算的。此外,对400名内科医生进行了调查,并询问他们向老年患者推荐PPSV23再接种的原因。总共有1648名老年人至少接种过一剂PPSV23;其中,58人至少接种过两次(再接种覆盖率:3.5%)。在接受调查的医生中,最常被提及的PPSV23再接种理由是再接种的益处超过了再接种的风险。此外,多变量分析显示,在老年受试者中,再接种状态与同龄人(如配偶、家人、朋友)的建议关联最为紧密。本研究首次报告了日本65岁及以上成年人中PPSV2再接种覆盖率,并得出覆盖率非常低的结论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/08006ee50b84/KHVI_A_1717184_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/7dc3728fb14e/KHVI_A_1717184_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/a22a44660177/KHVI_A_1717184_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/72896995fea4/KHVI_A_1717184_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/08006ee50b84/KHVI_A_1717184_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/7dc3728fb14e/KHVI_A_1717184_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/a22a44660177/KHVI_A_1717184_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/72896995fea4/KHVI_A_1717184_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9f/7553671/08006ee50b84/KHVI_A_1717184_F0004_B.jpg

相似文献

1
A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude.一项针对日本65岁及以上老年人的23价肺炎球菌多糖疫苗(PPSV23)再接种覆盖率及医生态度的全国性调查。
Hum Vaccin Immunother. 2020 Sep 1;16(9):2292-2299. doi: 10.1080/21645515.2020.1717184. Epub 2020 Feb 11.
2
A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.日本一项针对 50 岁及以上患有慢性疾病的患者的 23 价肺炎球菌荚膜多糖疫苗(PPSV23)接种覆盖率的全国性调查。
Hum Vaccin Immunother. 2020 Jul 2;16(7):1521-1528. doi: 10.1080/21645515.2019.1690332. Epub 2019 Dec 4.
3
Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.在日本老年人中使用23价肺炎球菌多糖疫苗进行再接种耐受性良好,并能引发免疫反应。
Vaccine. 2016 Jul 19;34(33):3875-81. doi: 10.1016/j.vaccine.2016.05.052. Epub 2016 Jun 10.
4
Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey.与日本老年人中 PPSV23 覆盖率相关的因素:一项全国性的基于社区的调查。
BMJ Open. 2019 Jul 16;9(7):e030197. doi: 10.1136/bmjopen-2019-030197.
5
Correlation between family physician's direct advice and pneumococcal vaccination intention and behavior among the elderly in Japan: a cross-sectional study.日本老年人中家庭医生的直接建议与肺炎球菌疫苗接种意愿及行为之间的相关性:一项横断面研究
BMC Fam Pract. 2018 Sep 5;19(1):153. doi: 10.1186/s12875-018-0841-3.
6
Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.5 年以上时间间隔进行 23 价肺炎球菌多糖疫苗复种不会影响日本老年人的免疫原性和安全性。
Hum Vaccin Immunother. 2018;14(8):1931-1938. doi: 10.1080/21645515.2018.1456611. Epub 2018 May 14.
7
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.13价肺炎球菌结合疫苗在70岁及以上曾接种23价肺炎球菌多糖疫苗的成年人中的免疫原性和安全性。
Vaccine. 2013 Aug 2;31(35):3585-93. doi: 10.1016/j.vaccine.2013.05.010. Epub 2013 May 18.
8
Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.肺炎球菌多糖 23 价疫苗:成人再次接种后循环抗体和免疫原性及安全性的长期持久性。
Vaccine. 2012 Jun 22;30(30):4435-44. doi: 10.1016/j.vaccine.2012.04.052. Epub 2012 Apr 26.
9
Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).更新的 23 价肺炎球菌多糖疫苗(PPSV23)预防成人侵袭性肺炎球菌病的建议。
MMWR Morb Mortal Wkly Rep. 2010 Sep 3;59(34):1102-6.
10
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.成人序贯接种 13 价肺炎球菌结合疫苗和 23 价肺炎球菌多糖疫苗 1 年后抗体的持久性。
Hum Vaccin Immunother. 2019;15(3):575-583. doi: 10.1080/21645515.2018.1538618. Epub 2019 Jan 16.

引用本文的文献

1
Pneumococcal disease burden in high-risk older adults: Exploring impact of comorbidities, long-term care facilities, antibiotic resistance, and immunization policies through a narrative literature review.高危老年人群中的肺炎球菌疾病负担:通过叙述性文献综述探讨合并症、长期护理机构、抗生素耐药性及免疫政策的影响
Hum Vaccin Immunother. 2024 Dec 31;20(1):2429235. doi: 10.1080/21645515.2024.2429235. Epub 2024 Dec 4.
2
Drivers of and barriers to routine adult vaccination: A systematic literature review.成人常规疫苗接种的驱动因素和障碍:系统文献回顾。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2127290. doi: 10.1080/21645515.2022.2127290. Epub 2022 Oct 5.
3

本文引用的文献

1
Factors associated with pneumococcal vaccination in elderly people: a cross-sectional study among elderly club members in Miyakonojo City, Japan.与老年人肺炎球菌疫苗接种相关的因素:日本宫崎市老年人俱乐部成员的横断面研究。
BMC Public Health. 2018 Oct 12;18(1):1172. doi: 10.1186/s12889-018-6080-7.
2
The impact on vaccination coverage following introduction of a routine pneumococcal vaccination programme for the elderly in Japan.日本为老年人推出常规肺炎球菌疫苗接种计划后,对疫苗接种覆盖率的影响。
Vaccine. 2018 Sep 18;36(39):5886-5890. doi: 10.1016/j.vaccine.2018.08.023. Epub 2018 Aug 22.
3
Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Burden of illness associated with pneumococcal infections in Japan - a targeted literature review.
日本肺炎球菌感染相关疾病负担——一项针对性文献综述
J Mark Access Health Policy. 2021 Dec 27;10(1):2010956. doi: 10.1080/20016689.2021.2010956. eCollection 2022.
5 年以上时间间隔进行 23 价肺炎球菌多糖疫苗复种不会影响日本老年人的免疫原性和安全性。
Hum Vaccin Immunother. 2018;14(8):1931-1938. doi: 10.1080/21645515.2018.1456611. Epub 2018 May 14.
4
Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan.日本国家常规疫苗接种计划对老年人23价肺炎球菌多糖疫苗接种率的影响。
J Infect Chemother. 2018 Jun;24(6):496-498. doi: 10.1016/j.jiac.2018.01.004. Epub 2018 Feb 3.
5
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017.美国免疫实践咨询委员会2017年19岁及以上成年人推荐免疫接种时间表
MMWR Morb Mortal Wkly Rep. 2017 Feb 10;66(5):136-138. doi: 10.15585/mmwr.mm6605e2.
6
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.23 价肺炎球菌多糖疫苗对 65 岁及以上老年人肺炎球菌性肺炎的血清型特异性效力:一项多中心、前瞻性、病例对照设计研究。
Lancet Infect Dis. 2017 Mar;17(3):313-321. doi: 10.1016/S1473-3099(17)30049-X. Epub 2017 Jan 24.
7
Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.23价肺炎球菌多糖疫苗再次接种在老年人中的有效性、免疫原性及安全性:一项系统评价
BMC Infect Dis. 2016 Nov 25;16(1):711. doi: 10.1186/s12879-016-2040-y.
8
Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.加泰罗尼亚低风险、中风险和高风险成年人的肺炎球菌疫苗接种覆盖率。
Hum Vaccin Immunother. 2016 Nov;12(11):2953-2958. doi: 10.1080/21645515.2016.1210744. Epub 2016 Jul 25.
9
Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.在日本老年人中使用23价肺炎球菌多糖疫苗进行再接种耐受性良好,并能引发免疫反应。
Vaccine. 2016 Jul 19;34(33):3875-81. doi: 10.1016/j.vaccine.2016.05.052. Epub 2016 Jun 10.
10
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.美国成年人中需要住院治疗的社区获得性肺炎
N Engl J Med. 2015 Jul 30;373(5):415-27. doi: 10.1056/NEJMoa1500245. Epub 2015 Jul 14.